The global Lupus Therapeutic Market is estimated to be valued at US$ 3035.59 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Lupus therapeutics are drugs used for the treatment of systemic lupus erythematosus (SLE). SLE is an autoimmune disease in which the immune system attacks the body's own cells and tissue. Biologics are widely used medications for refractory cases as they help reduce disease activity and prevent organ damage.
Market key trends:
One of the key trends in the lupus therapeutics market is growing preference for biologics over conventional drugs. Biologics have shown high efficacy and safety in controlling disease symptoms with minimal side effects. For example, Belimumab (Benlysta) was the first biologic approved by the US FDA in 2011 for the treatment of SLE. It demonstrated high response rates and favorable safety profile over standard care. With continuous research, newer biologics with novel mechanisms of action are in pipeline which is expected to drive the market during the forecast period.
Segment Analysis
The global Lupus therapeutic market is dominated by systemic lupus erythematosus (SLE) segment, which accounts for more than 60% market share. SLE is the most common type of lupus and can potentially damage any part of the body like joints, skin, blood cells, kidneys, and brain. With no permanent cure available for SLE, the treatment emphasis is on managing symptoms and minimizing flares.
Key Takeaways
The Global Lupus Therapeutics Market Size is expected to witness high growth, exhibiting CAGR of 8.6% over the forecast period, due to increasing prevalence of lupus disorders worldwide.
Regional analysis
North America dominates the global Lupus therapeutic market with over 35% market share. Higher lupus disease awareness, growing healthcare expenditure, and availability of advanced treatment options are responsible for its predominance in the region. Asia Pacific is poised to grow at the fastest pace during the forecast period owing to its large population base affected with lupus, improving healthcare infrastructure, and entry of global pharmaceutical players in developing countries like India and China.
Key players
Key players operating in the Lupus therapeutic market are Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
For More Insights, Read: https://www.newsstatix.com/lupus-therapeutic-market-size-share-and-growth-forecast-2023-2030/
Comments
0 comment